Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A

J Virol. 1997 Aug;71(8):5871-7. doi: 10.1128/JVI.71.8.5871-5877.1997.

Abstract

Human immunodeficiency virus type 1 (HIV-1) normally enters cells by direct fusion with the plasma membrane. In this report, HIV-1 particles capable of infecting cells through an endocytic pathway are described. Chimeric viruses composed of the HIV-1 core and the envelope glycoprotein of vesicular stomatitis virus (VSV-G) were constructed and are herein termed HIV-1(VSV) pseudotypes. HIV-1(VSV) pseudotypes were 20- to 130-fold more infectious than nonpseudotyped HIV-1. Infection by HIV-1(VSV) pseudotypes was markedly diminished by ammonium chloride and concanamycin A, a selective inhibitor of vacuolar H+ ATPases, demonstrating that these viruses require endosomal acidification to achieve productive infection. HIV-1 is thus capable of performing all of the viral functions necessary for infection when entry is targeted to an endocytic route. Maximal HIV-1 infectivity requires the presence of the viral Nef protein and the cellular protein cyclophilin A (CyPA) during virus assembly. Pseudotyping by VSV-G markedly suppressed the requirement for Nef. HIV-1(VSV) particles were also resistant to inhibition by cyclosporin A; however, the deleterious effect of a gag mutation inhibiting CyPA incorporation was not relieved by VSV-G. These results suggest that Nef acts at a step of the HIV-1 life cycle that is either circumvented or facilitated by targeting virus entry to an endocytic pathway. The findings also support the hypothesis that Nef and CyPA enhance HIV-1 infectivity through independent processes and demonstrate a mechanistic difference between reduction of HIV-1 infectivity by cyclosporin A and gag mutations that decrease HIV-1 incorporation of CyPA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Isomerases / physiology
  • Carrier Proteins / physiology
  • Cyclosporine / metabolism
  • Cyclosporine / pharmacology*
  • Endocytosis*
  • Gene Products, gag / metabolism
  • Gene Products, nef / physiology*
  • HIV-1 / drug effects
  • HIV-1 / physiology*
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Membrane Glycoproteins*
  • Peptidylprolyl Isomerase
  • Viral Envelope Proteins / physiology*
  • nef Gene Products, Human Immunodeficiency Virus

Substances

  • Carrier Proteins
  • G protein, vesicular stomatitis virus
  • Gene Products, gag
  • Gene Products, nef
  • Immunosuppressive Agents
  • Membrane Glycoproteins
  • Viral Envelope Proteins
  • nef Gene Products, Human Immunodeficiency Virus
  • Cyclosporine
  • Amino Acid Isomerases
  • Peptidylprolyl Isomerase